[Comment] A decade of transformation in MASLD: from nomenclature to novel therapies | ClinicLens
Over the past decade, metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading cause of chronic liver disease worldwide, affecting over 1·27 billion people, with prevalence predicted to continue increasing until 2040.1 The multisystem nature of
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.